Research will be conducted in an effort to establish basic abnormalities in the function of the immune system leading to thyroid autoimmunity and the clinical disease syndromes of Graves' disease, thyroiditis, and idiopathic myxedema. Thyroid microsomal antigen will be solubilized, purified by immunoabsorption or immunoprecipitation, separated by electrophoresis, and identified by Western Blotting. Cell surface and membrane proteins will be iodinated or labeled with 35S methionine. Proteins will be separated by electrophoresis and antigens will be detected by Western Blot. Preliminary studies have shown that different sera recognize different antigen epitopes in non-denaturing, denaturing, or reduced and denaturing conditions. We will relate the type of antibody reaction pattern to the clinical features of the disease. Preliminary data has suggested that the microsomal antigen is closely related to thyroid peroxidase, and a variety of studies will be pursued in order to prove or disprove this possibility. We will detect different epitopes on the microsomal antigen using cyanogen bromide or protease V8 fragmentation of the antigen and Western blotting or column techniques. An attempt will be made to identify the specific antigens to which patients with AITD most frequently are immunized. In order to study function of the feedback control system regulating microsomal antibody production, we will look for microsomal antigen in serum, and will develop methods for recognizing anti-idiotype antibodies directed against microsomal antibody epitopes. T cell reactivity to microsomal antigen will be characterized using lymphocytes from peripheral blood, thyroid tissue, or neck lymph nodes. T cell clones will be developed using a soft agar culture or test tube incubation system. The T cell lines will be used in studies of control of B cell function and in vitro reactivity with autologous thyroid cells. If sufficient time is available, we will attempt to clone the gene for the microsomal antigen and assess differences in structure or expression of the gene.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK027384-08
Application #
3228270
Study Section
Immunological Sciences Study Section (IMS)
Project Start
1980-07-01
Project End
1989-06-30
Budget Start
1988-07-01
Budget End
1989-06-30
Support Year
8
Fiscal Year
1988
Total Cost
Indirect Cost
Name
University of Chicago
Department
Type
Schools of Medicine
DUNS #
225410919
City
Chicago
State
IL
Country
United States
Zip Code
60637
Inaba, Hidefumi; Moise, Leonard; Martin, William et al. (2013) Epitope recognition in HLA-DR3 transgenic mice immunized to TSH-R protein or peptides. Endocrinology 154:2234-43
Inaba, Hidefumi; Martin, William; Ardito, Matt et al. (2010) The role of glutamic or aspartic acid in position four of the epitope binding motif and thyrotropin receptor-extracellular domain epitope selection in Graves' disease. J Clin Endocrinol Metab 95:2909-16
De Groot, L J; Shin, Y Ha; Pan, D et al. (2009) Evaluation of T cell stimulation by thyrotropin-receptor epitopes in Graves' disease. J Endocrinol Invest 32:52-6
Inaba, Hidefumi; Martin, William; De Groot, Anne S et al. (2006) Thyrotropin receptor epitopes and their relation to histocompatibility leukocyte antigen-DR molecules in Graves' disease. J Clin Endocrinol Metab 91:2286-94
Takara, Masaki; Kouki, Tsuyoshi; DeGroot, Leslie J (2003) CTLA-4 AT-repeat polymorphism reduces the inhibitory function of CTLA-4 in Graves' disease. Thyroid 13:1083-9
Gardine, C A; Gentile, F; Pellegrini, C et al. (2003) Multiple fragments of human TG are capable of inducing oral tolerance to whole human TG. J Endocrinol Invest 26:294-300
Kouki, T; Gardine, C A; Yanagawa, T et al. (2002) Relation of three polymorphisms of the CTLA-4 gene in patients with Graves' disease. J Endocrinol Invest 25:208-13
Gardine, C A; Kouki, T; DeGroot, L (2001) Characterization of the T lymphocyte subsets and lymphoid populations involved in the induction of low-dose oral tolerance to human thyroglobulin. Cell Immunol 212:1-15
Kouki, T; Sawai, Y; Gardine, C A et al. (2000) CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J Immunol 165:6606-11
White, D M; Takeda, T; DeGroot, L J et al. (1997) Beta-trace gene expression is regulated by a core promoter and a distal thyroid hormone response element. J Biol Chem 272:14387-93

Showing the most recent 10 out of 56 publications